Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 611-915-5 | CAS number: 59941-98-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Genetic toxicity: in vitro
Administrative data
- Endpoint:
- in vitro gene mutation study in mammalian cells
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- 2017
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 017
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 490 (In Vitro Mammalian Cell Gene Mutation Tests Using the Thymidine Kinase Gene)
- Version / remarks:
- adopted 29 July 2016
- GLP compliance:
- yes
- Type of assay:
- in vitro mammalian cell transformation assay
Test material
- Reference substance name:
- N-{4-[(4,6-dimethylpyrimidin-2-yl)sulfamoyl]phenyl}-2-methylprop-2-enamide
- EC Number:
- 611-915-5
- Cas Number:
- 59941-98-9
- Molecular formula:
- C16 H18 N4 O3 S
- IUPAC Name:
- N-{4-[(4,6-dimethylpyrimidin-2-yl)sulfamoyl]phenyl}-2-methylprop-2-enamide
- Test material form:
- solid: particulate/powder
- Remarks:
- white crystalline
Constituent 1
Method
- Target gene:
- thymidine kinase (TK)
Species / strain
- Species / strain / cell type:
- mouse lymphoma L5178Y cells
- Details on mammalian cell type (if applicable):
- CELLS USED
- Source of cells: American Type Culture Collection, (ATCC, Manassas, USA) (2001).
- Suitability of cells: Recommended test system in international guidelines (e.g. OECD).
- Stock cultures of the cells were stored in liquid nitrogen (-196°C). The cultures were checked for mycoplasma contamination. Cell density was kept below 1 x 106 cells/ml.
MEDIA USED
Horse serum
Horse serum (Life Technologies) was inactivated by incubation at 56°C for at least 30 minutes.
Basic medium
RPMI 1640 Hepes buffered medium (Dutch modification) (Life Technologies) containing penicillin/streptomycin (50 U/ml and 50 μg/ml, respectively) (Life Technologies), 1 mM sodium pyruvate (Sigma, Zwijndrecht, The Netherlands) and 2 mM L-glutamin (Life Technologies).
Growth medium
Basic medium, supplemented with 10% (v/v) heat-inactivated horse serum (=R10 medium).
Exposure medium
Cells were exposed to the test item in basic medium supplemented with 5% (v/v)
heat-inactivated horse serum (R5-medium).
Selective medium
Selective medium consisted of basic medium supplemented with 20% (v/v) heat-inactivated horse serum (total amount of serum = 20%, R20-medium) and 5 µg/ml trifluorothymidine (TFT) (Sigma).
Non-selective medium
Non-selective medium consisted of basic medium supplemented with 20% (v/v)
heat-inactivated horse serum (total amount of serum = 20%, R20-medium). - Additional strain / cell type characteristics:
- not applicable
- Metabolic activation:
- with and without
- Metabolic activation system:
- Rat liver microsomal enzymes (S9 homogenate)
- Test concentrations with justification for top dose:
- In the dose-range finding test, L5178Y mouse lymphoma cells were treated with a test item concentration range of 125 to 2000 µg/ml in the absence and presence ofS9-mix with a 3 hour treatment period.
Based on the results of the dose range finding test, the following dose ranges were selected for the mutagenicity test:
Without S9-mix: 63, 125, 250, 500, 600, 700, 800, 850, 900, 950 and 1000 μg/ml exposure medium.
With S9-mix: 250, 500, 750, 1000, 1200, 1400, 1500, 1600, 1700, 1800 and
1900 μg/ml exposure medium. - Vehicle / solvent:
- The vehicle for the test item was dimethyl sulfoxide (SeccoSolv, Merck Darmstadt, Germany).
Rationale: The test substance was solvable in this vehicle.
Controls
- Untreated negative controls:
- yes
- Remarks:
- The negative control was dimethyl sulfoxide (DMSO), the vehicle of the test item.
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- cyclophosphamide
- methylmethanesulfonate
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in medium
- Cell density at seeding (if applicable): 8 x 10^6 cells (10^6 cells/ml for 3 hour treatment) or 6 x 10^6 cells (1.25 x 10^5 cells/ml for 24 hour treatment)
DURATION
- Preincubation period:
Prior to dose-range finding and mutagenicity testing, the mouse lymphoma cells were grown for 1 day in R10-medium containing 10^-4 M hypoxanthine (Sigma), 2 x 10^-7 M aminopterine (Fluka Chemie AG, Buchs, Switzerland) and 1.6 x 10^-5 M thymidine (Sigma) (HAT-medium) to reduce the amount of spontaneous mutants, followed by a recovery period of 2 days on R10-medium containing hypoxanthine and thymidine only. After this period cells were returned to R10-medium for at least 1 day before starting the experiment.
- Exposure duration: 3 and 24 hours
- Expression time (cells in growth medium): For expression of the mutant phenotype, the remaining cells were cultured for 2 days after the treatment period.
- Fixation time (start of exposure up to fixation or harvest of cells): The microtiter plates were incubated for 11 or 12 days to determine the cloning efficiency and the mutation frequency.
METHODS OF SLIDE PREPARATION AND STAINING TECHNIQUE USED:
After the incubation period, the plates for the TFT-selection were stained for 2 hours, by adding 0.5 mg/ml
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) (Sigma) to each well. The plates for the CE day2 and MF were scored with the naked eye or with the microscope.
NUMBER OF CELLS EVALUATED:
For determination of the CEday2 the cell suspensions were diluted and seeded in wells of a 96-well dish. One cell was added per well (2 x 96-well microtiter plates/concentration) in non-selective medium.
For determination of the mutation frequency (MF) a total number of 9.6 x 10^5 cells per concentration were plated in five 96-well microtiter plates, each well containing 2000 cells in selective medium (TFT-selection), with the exception of the positive control groups (MMS and CP) where a total number of 9.6 x 10^5 cells/concentration were plated in ten 96-well microtiter plates, each well containing 1000 cells in selective medium (TFT-selection).
DETERMINATION OF CYTOTOXICITY
- Method: cell growth and cloning efficiency
- Any supplementary information relevant to cytotoxicity:
OTHER EXAMINATIONS:
The colonies were divided into small and large colonies. Mutant cells that have suffered extensive genetic damage have prolonged doubling times and thus form small colonies. Less severely affected mutant cells grow at rates similar to the parental cells and form large colonies. The small colonies can be associated with the induction of chromosomal mutations. The large colonies appear to result from mutants with single gene mutations (substitutions, deletions of base-pairs) affecting the TK gene.
The small colonies are morphologically dense colonies with a sharp contour and with a diameter less than a quarter of a well. The large colonies are morphologically less dense colonies with a hazy contour and with a diameter larger than a quarter of a well. A well containing more than one small colony is classified as one small colony. A well containing more than one large colony is classified as one large colony. A well containing one small and one large colony is classified as one large colony.
- OTHER: - Rationale for test conditions:
- All incubations were carried out in a humid atmosphere (80 - 100%, actual range 65 - 93%) containing 5.0 ± 0.5% CO2 in air in the dark at 37.0 ± 1.0°C (actual range 35.4 - 37.4°C).
- Evaluation criteria:
- In addition to the criteria stated below, any increase of the mutation frequency should be evaluated for its biological relevance including comparison of the results with the historical control data range.
The global evaluation factor (GEF) has been defined by the IWGT as the mean of the negative/solvent MF distribution plus one standard deviation. For the micro well version of the assay the GEF is 126.
A test item is considered positive (mutagenic) in the mutation assay if it induces a MF of more than MF(controls) + 126 in a dose-dependent manner. An observed increase should be biologically relevant and will be compared with the historical control data range.
A test item is considered equivocal (questionable) in the mutation assay if no clear conclusion for positive or negative result can be made after an additional confirmation study.
A test item is considered negative (not mutagenic) in the mutation assay if: none of the tested concentrations reaches a mutation frequency of MF(controls) + 126.
Results and discussion
Test resultsopen allclose all
- Species / strain:
- mouse lymphoma L5178Y cells
- Metabolic activation:
- with
- Genotoxicity:
- positive
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- the dose levels of 1700, 1800 and 1900 μg/ml were not used for mutation frequency measurement, since these dose levels were too toxic for further testing.
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Species / strain:
- mouse lymphoma L5178Y cells
- Metabolic activation:
- without
- Genotoxicity:
- positive
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- the dose levels of 900, 950 and 1000 μg/ml were not used for mutation frequency measurement, since these dose levels were too toxic for further testing.
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Additional information on results:
- RANGE-FINDING/SCREENING STUDIES:
In the absence of S9-mix, the relative suspension growth was 8% at the test item concentration of 1000 μg/ml compared to the relative suspension growth of the solvent control. No cell survival was observed at the test item concentration of 2000 μg/ml.
In the presence of S9-mix, the relative suspension growth was 68% at the test item concentration of 1000 μg/ml compared to the relative suspension growth of the solvent control. Hardly any cell survival was observed at the test item concentration of 2000 μg/ml.
Based on the results of the dose range finding test, the following dose ranges were selected for the mutagenicity test:
Without S9-mix: 63, 125, 250, 500, 600, 700, 800, 850, 900, 950 and 1000 μg/ml exposure medium.
With S9-mix: 250, 500, 750, 1000, 1200, 1400, 1500, 1600, 1700, 1800 and
1900 μg/ml exposure medium.
HISTORICAL CONTROL DATA (with ranges, means and standard deviation and confidence interval (e.g. 95%):
Mutation frequency per 10^6 survivors [95% conficence interval]
- Positive historical control data:
3-hour treatment: 857 [289 - 1425]
24-hour treatment: 1710 [-793 - 4214]
- Negative (solvent/vehicle) historical control data:
3-hour treatment: 86 [36 - 135]
24-hour treatment: 87 [28 - 145]
The mutation frequency found in the solvent control cultures was within the acceptability criteria of this assay and within the 95% control limits of the distribution of the historical negative control database.
Positive control chemicals, methyl methanesulfonate and cyclophosphamide, both produced significant increases in the mutation frequency. In addition, the mutation frequency found in the positive control cultures was within the 95% control limits of the distribution of the historical positive control database. It was therefore concluded that the test conditions were adequate and that the metabolic activation system (S9-mix) functioned properly.
OTHER:
The suspension growth over the two-day expression period for cultures treated with DMSO was 19 and 20.
In the presence of S9-mix, V123109 induced dose related increases in the mutation frequency. The increases were above the 95% control limits of the distribution of the historical negative control database and also above the GEF + MF(controls) (220 per 106 survivors).
Although the increases in the mutation frequency at the TK locus were only observed at toxic dose levels (RTG ≤21%), the mutation frequencies at these concentrations were above the GEF and the results are considered to be biological relevance and the test item is mutagenic at toxic dose levels
Applicant's summary and conclusion
- Conclusions:
- V123109 is mutagenic in the TK mutation test system under the experimental conditions described in this report.
- Executive summary:
The objective of this study was to evaluate the mutagenic potential of V123109 by testing its ability to induce forward mutations at the thymidine kinase (TK) locus in L5178Y mouse lymphoma cells, either in the absence or presence of a metabolic system (S9-mix). The TK mutational system detects base pair mutations, frame shift mutations and small deletions.
The test was performed in the absence and presence of S9-mix with a 3 hour treatment period.
The study procedures described in this report were based on the most recent OECD guideline (OECD 490, 29 July 2016).
Batch V123109/SA of V123109 was a white crystalline powder with a purity of >95%. The test item was dissolved in dimethyl sulfoxide
In the mutation experiment, V123109 was tested up to concentrations of 850 and 1500 µg/ml in the absence and presence S9-mix, respectively. The incubation time was 3 hours. Relative total growth (RTG) was reduced to 14 and 15% compared to the negative control in the absence and presence of S9-mix, respectively. Above the dose level of 1500 µg/ml the RTG was below the acceptable limit of 10%. The test item did not precipitate in the culture medium up to the concentration of 1500 µg/ml.
The mutation frequency found in the solvent control cultures was within the acceptability criteria of this assay and within the 95% control limits of the distribution of the historical negative control database.
Positive control chemicals, methyl methanesulfonate and cyclophosphamide, both produced significant increases in the mutation frequency. In addition, the mutation frequency found in the positive control cultures was within the 95% control limits of the distribution of the historical positive control database. It was therefore concluded that the test conditions were adequate and that the metabolic activation system (S9-mix) functioned properly.
In the absence of S9-mix, V123109 induced dose related increases in the mutation frequency. The increases were above the95% control limits of the distribution of the historical negative control databaseand also abovethe GEF + MF(controls)(225per 106survivors).
In the presence of S9-mix, V123109 induced dose related increases in the mutation frequency. The increases were above the95% control limits of the distribution of the historical negative control databaseand also abovethe GEF + MF(controls)
(220per 106survivors).Although the increases in the mutation frequency at the TK locus were only observed at toxic dose levels (RTG ≤21%), the mutation frequencies at these concentrations were above the GEF and the results are therefore considered to be biological relevance and the test item mutagenic at toxic dose levels.
In conclusion, V123109 is mutagenic in the mouse lymphoma L5178Y test system under the experimental conditions described in this report.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.